Clinical trial

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

NCT03294694

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Ribociclib Normalized identity: ribociclibView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention PDR001 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2017-11-08

PhasePHASE1

Conditions

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancerunresolved

HER2-Negative Breast Cancerunresolved

Metastatic Epithelial Ovarian Cancerunresolved

Interventions

RibociclibDRUG · verified · RxNorm: ribociclib

PDR001DRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Novartiscollaborator

Mapped research locations

BostonMassachusetts, United States3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03294694 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.